-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下：安森美半导体（ON）第一季度营收为15.13亿美元，环比下降1%，同比增长5%，高于市场普遍预期的14.88亿美元。非GAAP毛利率为38.5%，环比增长250个基点。营业收入同比增长10%，营收增长5%，凸显了其商业模式中蕴含的2倍运营杠杆。人工智能数据中心业务同比增长超过一倍，环比加速30%，鉴于其高端应用特性，这将成为推动营收增长和利润率提升的重要长期催化剂。安森美半导体预计第二季度营收为15.35亿美元至16.35亿美元，每股收益为0.65美元至0.77美元，略高于市场普遍预期的15.32亿美元营收和0.67美元每股收益。我们同意管理层的评估，即安永已经走出了周期性低谷，并已做好准备继续扩大利润率，这得益于积极的资本回报，包括3.46亿美元的股票回购（占2.17亿美元自由现金流的160%）以及拥有24亿美元现金的强劲资产负债表，为增长投资提供了灵活性。
Related Articles
Asia
Westpac's Total Capital, CET1 Capital Up Year on Year in March Quarter
Westpac Banking (ASX:WBC, NZE:WBC) total capital and Common Equity Tier 1 (CET1) capital both increased year-over-year in the March quarter, according to a Tuesday Australian bourse filing.The bank's total capital in the three months to March came in at AU$98.54 billion, up from the AU$97.14 billion it reported in the year-ago period. Its CET1 capital for the period clocked in at AU$56.94 billion, rising from the AU$55.01 billion it reported for the March 2025 quarter.Its CET1 ratio for the March quarter was 12.4%, compared with a ratio of 12.2% in the prior-year period. It reported a liquidity coverage ratio of 132% for the quarter, compared with 135% in the same period in the previous year.
$ASX:WBC$NZE:WBC
Research
Research Alert: CFRA Raises Opinion On Shares Of Gildan Activewear To Buy From Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month price target of CAD98, based on 16.0x our 2026 EPS estimate and above the company's five-year average forward P/E multiple of 12.9x, reflecting our view that the company deserves an above-peer multiple. We view the recent acquisition of HanesBrands as positive and believe the company will improve Hanes' operating efficiency while capitalizing on significant synergies. GIL reported Q1 2026 results that reflect the significant impact of its HanesBrands acquisition, with revenues increasing 64% to $1.17B, $18M above estimates, while facing substantial integration-related charges. Adjusted EPS from continuing operations declined to $0.43 from $0.59, $0.08 above consensus estimates, reflecting higher share count from the acquisition and ongoing integration expenses. We now view shares more positively after a 20% decline from its 52-week high just a few months ago. Shares currently trade at 13.5x the midpoint of the company's full-year EPS guidance.
$GIL
Asia
Medibank Private Reports Policyholder Growth in Nine Months to March 31, Maintains Outlook
Medibank Private (ASX:MPL) reported policyholder growth of 22,400 in its resident private health insurance business in the nine months to March 31, up 25% from the same period a year earlier, according to a Tuesday filing with the Australian bourse.The company said the resident private health insurance industry has become more competitive in recent months, with data showing consumers increasingly prioritizing value and some participants resorting to price-led customer propositions."While no new material trends have emerged in 2026, Medibank will continue to monitor utilization given historic behavior and competitor activity as we remain disciplined," it said.Medibank maintained its fiscal 2026 guidance, saying it does not expect global events and volatility to have a direct impact on its businesses.The company's main financial exposure is through its investment portfolio, which includes about AU$188 million of investments in equities, and through movements in Australia's cash rate where it flagged a roughly AU$7 million annual impact to investment income.
$ASX:MPL